Innate Pharma Stock Forecast

Stock Price Forecast

According to 2 analysts polled by S&P Global, Innate Pharma stock has a consensus rating of "Strong Buy" and an average price target of €5.35. The average 1-year stock price forecast is 247.40% higher than the current stock price, while the lowest is €4.50 (+192.21%) and the highest is €6.20 (+302.60%).

Price Target: €5.35 (+247.40%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	€4.50	€5.35	€5.35	€6.20
Change	+192.21%	+247.40%	+247.40%	+302.60%

Analyst Ratings

The average analyst rating for Innate Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Sep '25	Oct '25	Nov '25	Jan '26	Feb '26	Mar '26
Strong Buy	2	2	2	2	1	2
Buy	0	0	0	0	0	0
Hold	1	1	1	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	2	1	2

Financial Forecast

Revenue This Year

31.21M

from 9.01M

246.64%

from 9.01M

Revenue Next Year

64.75M

from 31.21M

107.43%

from 31.21M

EPS This Year

0.95

from -

EPS Next Year

2.15

from 0.95

126.32%

from 0.95

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	24.70M	57.67M	61.64M	20.12M	9.01M	31.21M
Revenue Growth	-64.60%	133.47%	6.88%	-67.36%	-55.25%	246.64%
Operating Income	-47.83M	-16.43M	-12.67M	-51.58M	-54.01M	-26.83M
Net Income	-52.81M	-58.10M	-7.57M	-49.47M	-49.18M	-29.01M
EPS	-	-	-	-	-	0.95
Forward PE	-	-	-	4.33	2.99	1.62
Free Cash Flow	-15.02M	-32.74M	-27.07M	17.12M	-34.07M	-19.20M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.

Revenue Forecast

Revenue	2026	2027	2028
High	100.0M
Avg	31.2M
Low	4.2M

Revenue Growth

Revenue Growth	2026	2027	2028
High	1,010.5%
Avg	246.6%
Low	-53.4%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	0.95
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-